Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong
LUGANO-SINGAPORE, 17 December, 2016 - Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report...








